UK Markets close in 39 mins
  • FTSE 100

    7,224.91
    +7.38 (+0.10%)
     
  • FTSE 250

    23,005.45
    -48.64 (-0.21%)
     
  • AIM

    1,237.28
    -2.62 (-0.21%)
     
  • GBP/EUR

    1.1861
    +0.0009 (+0.08%)
     
  • GBP/USD

    1.3819
    +0.0025 (+0.1810%)
     
  • BTC-GBP

    48,246.85
    +2,987.57 (+6.60%)
     
  • CMC Crypto 200

    1,546.73
    +65.92 (+4.45%)
     
  • S&P 500

    4,539.47
    +19.84 (+0.44%)
     
  • DOW

    35,625.42
    +168.11 (+0.47%)
     
  • GOLD FUTURES

    1,782.40
    +11.90 (+0.67%)
     
  • NIKKEI 225

    29,255.55
    +40.03 (+0.14%)
     
  • HANG SENG

    26,136.02
    +348.81 (+1.35%)
     
  • DAX

    15,528.83
    +13.00 (+0.08%)
     
  • CAC 40

    6,713.31
    +43.46 (+0.65%)
     

Global Myeloproliferative Disorders Drugs Market to Reach $9.9 Billion by 2027

·22-min read

Abstract: - Global Myeloproliferative Disorders Drugs Market to Reach $9. 9 Billion by 2027. - Amid the COVID-19 crisis, the global market for Myeloproliferative Disorders Drugs estimated at US$7.

New York, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Myeloproliferative Disorders Drugs Industry" - https://www.reportlinker.com/p06032290/?utm_source=GNW
8 Billion in the year 2020, is projected to reach a revised size of US$9.9 Billion by 2027, growing at aCAGR of 3.4% over the period 2020-2027. Ph+ Chronic myelogenous leukemia (CML), one of the segments analyzed in the report, is projected to record 3.2% CAGR and reach US$7.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Ph- Myeloproliferative Neoplasms (MPNs) segment is readjusted to a revised 4.1% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $2.1 Billion, While China is Forecast to Grow at 5.4% CAGR
- The Myeloproliferative Disorders Drugs market in the U.S. is estimated at US$2.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2027 trailing a CAGR of 5.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.1% and 2.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

- Select Competitors (Total 34 Featured) -

  • Bristol-Myers Squibb

  • Inctye

  • Novartis

  • Pfizer

  • Takeda

  • Teva




Read the full report: https://www.reportlinker.com/p06032290/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Myeloproliferative
Disorders Drugs by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Myeloproliferative Disorders
Drugs by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Myeloproliferative
Disorders Drugs by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Ph+ Chronic
myelogenous leukemia (CML) by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Ph+ Chronic myelogenous
leukemia (CML) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Ph+ Chronic myelogenous
leukemia (CML) by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

Table 7: World Current & Future Analysis for Ph-
Myeloproliferative Neoplasms (MPNs) by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Ph- Myeloproliferative
Neoplasms (MPNs) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Ph- Myeloproliferative
Neoplasms (MPNs) by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 10: USA Current & Future Analysis for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 11: USA Historic Review for Myeloproliferative Disorders
Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML)
and Ph- Myeloproliferative Neoplasms (MPNs) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 12: USA 15-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 &
2027

CANADA
Table 13: Canada Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 14: Canada Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 15: Canada 15-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 &
2027

JAPAN
Table 16: Japan Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 17: Japan Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 18: Japan 15-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 &
2027

CHINA
Table 19: China Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 20: China Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 21: China 15-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 &
2027

EUROPE
Table 22: Europe Current & Future Analysis for
Myeloproliferative Disorders Drugs by Geographic Region -
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 23: Europe Historic Review for Myeloproliferative
Disorders Drugs by Geographic Region - France, Germany, Italy,
UK, Spain, Russia and Rest of Europe Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 24: Europe 15-Year Perspective for Myeloproliferative
Disorders Drugs by Geographic Region - Percentage Breakdown of
Value Sales for France, Germany, Italy, UK, Spain, Russia and
Rest of Europe Markets for Years 2012, 2020 & 2027

Table 25: Europe Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 26: Europe Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 27: Europe 15-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 &
2027

FRANCE
Table 28: France Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 29: France Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 30: France 15-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 &
2027

GERMANY
Table 31: Germany Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 32: Germany Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 33: Germany 15-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 &
2027

ITALY
Table 34: Italy Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 35: Italy Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 36: Italy 15-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 &
2027

UNITED KINGDOM
Table 37: UK Current & Future Analysis for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 38: UK Historic Review for Myeloproliferative Disorders
Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML)
and Ph- Myeloproliferative Neoplasms (MPNs) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 39: UK 15-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 &
2027

SPAIN
Table 40: Spain Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 41: Spain Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 42: Spain 15-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 &
2027

RUSSIA
Table 43: Russia Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 44: Russia Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 45: Russia 15-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 &
2027

REST OF EUROPE
Table 46: Rest of Europe Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 47: Rest of Europe Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 48: Rest of Europe 15-Year Perspective for
Myeloproliferative Disorders Drugs by Indication - Percentage
Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia
(CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years
2012, 2020 & 2027

ASIA-PACIFIC
Table 49: Asia-Pacific Current & Future Analysis for
Myeloproliferative Disorders Drugs by Geographic Region -
Australia, India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 50: Asia-Pacific Historic Review for Myeloproliferative
Disorders Drugs by Geographic Region - Australia, India, South
Korea and Rest of Asia-Pacific Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 51: Asia-Pacific 15-Year Perspective for
Myeloproliferative Disorders Drugs by Geographic Region -
Percentage Breakdown of Value Sales for Australia, India, South
Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 &
2027

Table 52: Asia-Pacific Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 53: Asia-Pacific Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 54: Asia-Pacific 15-Year Perspective for
Myeloproliferative Disorders Drugs by Indication - Percentage
Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia
(CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years
2012, 2020 & 2027

AUSTRALIA
Table 55: Australia Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 56: Australia Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 57: Australia 15-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 &
2027

INDIA
Table 58: India Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 59: India Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 60: India 15-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 &
2027

SOUTH KOREA
Table 61: South Korea Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 62: South Korea Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 63: South Korea 15-Year Perspective for
Myeloproliferative Disorders Drugs by Indication - Percentage
Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia
(CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years
2012, 2020 & 2027

REST OF ASIA-PACIFIC
Table 64: Rest of Asia-Pacific Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 65: Rest of Asia-Pacific Historic Review for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 66: Rest of Asia-Pacific 15-Year Perspective for
Myeloproliferative Disorders Drugs by Indication - Percentage
Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia
(CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years
2012, 2020 & 2027

LATIN AMERICA
Table 67: Latin America Current & Future Analysis for
Myeloproliferative Disorders Drugs by Geographic Region -
Argentina, Brazil, Mexico and Rest of Latin America Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 68: Latin America Historic Review for Myeloproliferative
Disorders Drugs by Geographic Region - Argentina, Brazil,
Mexico and Rest of Latin America Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 69: Latin America 15-Year Perspective for
Myeloproliferative Disorders Drugs by Geographic Region -
Percentage Breakdown of Value Sales for Argentina, Brazil,
Mexico and Rest of Latin America Markets for Years 2012, 2020 &
2027

Table 70: Latin America Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 71: Latin America Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 72: Latin America 15-Year Perspective for
Myeloproliferative Disorders Drugs by Indication - Percentage
Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia
(CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years
2012, 2020 & 2027

ARGENTINA
Table 73: Argentina Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 74: Argentina Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 75: Argentina 15-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 &
2027

BRAZIL
Table 76: Brazil Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 77: Brazil Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 78: Brazil 15-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 &
2027

MEXICO
Table 79: Mexico Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 80: Mexico Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 81: Mexico 15-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 &
2027

REST OF LATIN AMERICA
Table 82: Rest of Latin America Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 83: Rest of Latin America Historic Review for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 84: Rest of Latin America 15-Year Perspective for
Myeloproliferative Disorders Drugs by Indication - Percentage
Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia
(CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years
2012, 2020 & 2027

MIDDLE EAST
Table 85: Middle East Current & Future Analysis for
Myeloproliferative Disorders Drugs by Geographic Region - Iran,
Israel, Saudi Arabia, UAE and Rest of Middle East Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 86: Middle East Historic Review for Myeloproliferative
Disorders Drugs by Geographic Region - Iran, Israel, Saudi
Arabia, UAE and Rest of Middle East Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 87: Middle East 15-Year Perspective for
Myeloproliferative Disorders Drugs by Geographic Region -
Percentage Breakdown of Value Sales for Iran, Israel, Saudi
Arabia, UAE and Rest of Middle East Markets for Years 2012,
2020 & 2027

Table 88: Middle East Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 89: Middle East Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 90: Middle East 15-Year Perspective for
Myeloproliferative Disorders Drugs by Indication - Percentage
Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia
(CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years
2012, 2020 & 2027

IRAN
Table 91: Iran Current & Future Analysis for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 92: Iran Historic Review for Myeloproliferative Disorders
Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML)
and Ph- Myeloproliferative Neoplasms (MPNs) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 93: Iran 15-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 &
2027

ISRAEL
Table 94: Israel Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 95: Israel Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 96: Israel 15-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 &
2027

SAUDI ARABIA
Table 97: Saudi Arabia Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 98: Saudi Arabia Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 99: Saudi Arabia 15-Year Perspective for
Myeloproliferative Disorders Drugs by Indication - Percentage
Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia
(CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years
2012, 2020 & 2027

UNITED ARAB EMIRATES
Table 100: UAE Current & Future Analysis for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 101: UAE Historic Review for Myeloproliferative Disorders
Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML)
and Ph- Myeloproliferative Neoplasms (MPNs) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 102: UAE 15-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 &
2027

REST OF MIDDLE EAST
Table 103: Rest of Middle East Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 104: Rest of Middle East Historic Review for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 105: Rest of Middle East 15-Year Perspective for
Myeloproliferative Disorders Drugs by Indication - Percentage
Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia
(CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years
2012, 2020 & 2027

AFRICA
Table 106: Africa Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 107: Africa Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 108: Africa 15-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2012, 2020 &
2027

IV. COMPETITION
Total Companies Profiled: 34
Read the full report: https://www.reportlinker.com/p06032290/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting